GenScript Biotech places 77,126,000 shares at HK$ 30.5 each in HK$ 2.35 billion deal

• GenScript Biotech priced a placing of 77,126,000 new shares at HK$ 30.5 each under its general mandate.
• Gross proceeds expected at HK$ 2.35 billion; net proceeds estimated at HK$ 2.33 billion; completion targeted on or before Sept. 15, 2026.
• Deal price implies a 4.7% discount to the Sept. 10 close of HK$ 32; shares equal 3.5% of existing capital.
• Net proceeds earmarked mainly for expansion of AI-driven drug discovery capacity, with additional funding for related R&D and working capital.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GenScript Biotech Corporation published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260911-12328610), on September 10, 2026, and is solely responsible for the information contained therein.